The Labcorp BioReference acquisition is an agreement to buy selected laboratory businesses and a prostate cancer test from a subsidiary of OPKO Health, for $722 million in cash plus a possible $150 million more. On 15 October 2026, Labcorp announced that it had agreed to acquire select assets of BioReference Health, LLC, which OPKO owns. Together the two figures give the “up to $872 million” in headlines, but that total assumes the full additional payment is earned and the closing price is not adjusted. The deal has not closed.
Here is what is being bought, how the money works, what changes (and does not) for patients and doctors, and the questions the announcement leaves unanswered.
Labcorp BioReference acquisition: key takeaways
- Price: $722 million in cash at closing, adjustable up or down based on closing business revenues, plus up to $150 million tied to revenue from the 4Kscore Test.
- Assets: BioReference’s clinical and women’s health testing, urology and corrections businesses, over 80 additional patient service centres and the 4Kscore Test.
- Revenue: Labcorp expects about $250 million in the first year after closing, based on its forecasts.
- Status: subject to regulatory approvals and customary closing conditions. No closing date was given.
- Scope: select assets only, not all of OPKO Health.
What Labcorp is buying in the Labcorp BioReference acquisition
The release lists BioReference’s laboratory businesses for clinical and women’s health testing, urology and correctional-facility testing, along with certain operational assets that include more than 80 additional patient service centres, the sites where patients give samples. It also includes the proprietary 4Kscore Test, which the release describes as an FDA-approved blood test that helps predict the likelihood of finding aggressive prostate cancer before a biopsy decision. The release does not name any assets that are excluded and does not give staff numbers for the acquired businesses.
How the money works in the Labcorp BioReference acquisition
The cash price is $722 million at closing, with an upward or downward adjustment possible based on closing business revenues. The extra payment of up to $150 million depends on revenue from the 4Kscore Test, but the release does not give the revenue threshold or the period over which it is measured. By our arithmetic, $722 million plus $150 million equals $872 million, which is where the headline total comes from; it is a ceiling, not a price.
Also by our arithmetic, the cash price is about 2.9 times the $250 million of expected first-year revenue, and the maximum total is about 3.5 times. Both are simple ratios built on Labcorp’s own forecast, not audited results, and the release gives no profit or accretion guidance. The release does not state how Labcorp will finance the purchase.
What happens between signing and closing of the Labcorp BioReference acquisition
An agreement is not a completed purchase. The release says the transaction is subject to regulatory approvals and customary closing conditions, without naming them or giving a target date. Until closing, the businesses continue under OPKO, and both companies operate independently. The final cash price can move because it is tied to closing business revenues, so the $722 million is a starting figure. In practice, readers should treat every number in this story as provisional until Labcorp or OPKO reports the transaction as completed.
What the Labcorp BioReference acquisition means for patients and doctors
Nothing changes until closing. The release says services will continue as they are. After closing, patients who use BioReference collection sites or doctors who send samples to its laboratories could see them become part of Labcorp’s network. Bryan Vaughn, Labcorp’s executive vice president and president of Diagnostics, said the acquisition “strengthens our ability to deliver affordable, high-quality, specialized diagnostic services.” How test menus, turnaround times or insurance contracts might change has not been announced.
Why OPKO is selling in the Labcorp BioReference acquisition
OPKO’s chairman and chief executive, Dr Phillip Frost, said the transaction “will allow OPKO to streamline operations and focus our resources on our biopharmaceutical business.” The release does not say how OPKO will use the proceeds. Labcorp says it has nearly 71,000 employees.
The 4Kscore Test in context
Prostate cancer is a common cancer, and decisions about biopsy after screening can be difficult. The National Cancer Institute has background. A test that estimates the likelihood of aggressive disease before a biopsy is meant to help patients and doctors decide whether the procedure is needed. The release gives no performance data for the test, so we do not assess how well it works here.
Risks and caveats for the Labcorp BioReference acquisition
- The deal has not closed and needs regulatory approvals. The release does not name them; in the US, merger review by bodies such as the Federal Trade Commission is common for deals of this kind, but that is our general note, not a statement in the release.
- The $150 million is contingent and its terms are not public.
- The $250 million revenue figure is a forecast. Actual results may differ.
- Integration of laboratories and collection sites can take time and may affect service.
In our assessment, the transaction is a targeted expansion rather than a transformation for Labcorp: a defined set of testing businesses, a collection-site network and a branded test, bought at a price that depends in part on that test’s future sales. Risk factors for both companies are in their filings on the SEC’s EDGAR database. For a related diagnostics story, see our report on preventive diagnostics in India and more in healthcare services.
What to watch next on the Labcorp BioReference acquisition
- Regulatory clearance and an expected closing date.
- Disclosure of the 4Kscore earnout terms.
- Any announced changes to collection sites, laboratories or test menus.
- Closing-price adjustments based on revenue.
Frequently asked questions
How much is Labcorp paying?
$722 million in cash at closing, with a possible additional payment of up to $150 million, so up to $872 million in total.
What is being acquired?
Select BioReference Health assets: clinical, women’s health, urology and corrections testing businesses, over 80 patient service centres and the 4Kscore Test.
Is OPKO Health being bought in the Labcorp BioReference acquisition?
No. Only selected assets of its BioReference Health subsidiary are included.
Has the Labcorp BioReference acquisition closed?
No. It is subject to regulatory approvals and customary closing conditions.
How we reported this: we relied on Labcorp’s announcement of 15 October 2026 and the quotations in it. Ratios and totals labelled as ours are our own arithmetic. Last updated: 16 October 2026. This article is news reporting and not investment advice.